There have been, and will be more, calls for personalized
medicine on the basis of genotyping. This narrative review,
originally written as one side of a debate, is on the basis of
learnings from > 40,000 patients in 40 years of a career
focused on stroke prevention, and is intended to be provocative.
I will argue from the perspective of a clinical pharmacologist
that rational use of already existing medical therapy,
on the basis of knowledge of clinical pharmacology and
on phenotyping our patients, could have a greater effect, and
could be implemented immediately, while awaiting the
development of cost-effective chips to guide therapy
Read the paper
No comments:
Post a Comment